|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000038692 |
|
最近更新日期: Date of Last Refreshed on: |
2020-12-13 20:36:33 |
|
注册时间: Date of Registration: |
2020-09-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
益母草注射液上市后在计划生育领域应用的多中心真实世界临床研究方案 |
|
Public title: |
A multi-center real-world study for the application of Motherwort injection in the field of family planning after market |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
益母草注射液上市后在计划生育领域应用的多中心真实世界临床研究方案 |
|
Scientific title: |
A multi-center real-world clinical research program for the application of Motherwort injection in the field of family planning after the market |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
万峰 |
研究负责人: |
武海英 |
|
Applicant: |
Wan Feng |
Study leader: |
wu haiying |
|
申请注册联系人电话: Applicant telephone: |
+86 13678038143 |
研究负责人电话:
Study leader's |
+86 13503713179 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13678038143@126.com |
研究负责人电子邮件: Study leader's E-mail: |
whysunnyzg@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省彭州市天彭镇东三环路二段133号 |
研究负责人通讯地址: |
河南省郑州市纬五路7号 |
|
Applicant address: |
133 Second Section of East Third Ring Road, Tianpeng Town, Pengzhou, Sichuan, China |
Study leader's address: |
7 Weiwu Road, Zhengzhou, He'nan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
成都第一制药有限公司 |
||
|
Applicant's institution: |
Chengdu first pharmaceutical |
||
|
研究负责人所在单位: |
河南省人民医院 |
||
|
Affiliation of the Leader: |
He'nan Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2019)伦审第(10)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河南省人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Henan Provincial People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-04-22 00:00:00 | ||
|
伦理委员会联系人: |
李立 |
||
|
Contact Name of the ethic committee: |
li li |
||
|
伦理委员会联系地址: |
河南省郑州市金水区纬五路7号省医科教大厦17楼 |
||
|
Contact Address of the ethic committee: |
17th Floor, Provincial Medical Science and Education Building, No. 7 Weiwu Road, Jinshui District, Zhengzhou City, Henan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
0371-87160680 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
河南省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Henan Provincial People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省郑州市金水区纬五路7号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 7 Weiwu Road, Zhengzhou City, Henan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
成都第一制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chengdu NO1. Pharmaceutical Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
流产、放置或取出节育器IUD |
||||||||||||||||||||||
|
Target disease: |
Abortion, placement or removal of an IUD |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
观察益母草注射液非干预、真实应用于流产、放置或取出IUD术后患者的状况,科学评价益母草注射液的有效性和安全性,为临床合理用药提供参考 |
||||||||||||||||||||||
|
Objectives of Study: |
To observe the situation of non-intervention and real application of Leonurus injection in patients after abortion, placement or removal of IUD, and to scientifically evaluate the efficacy and safety of Leonurus injection, so as to provide reference for rational clinical use of drugs |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
人流、放置或取出IUD术后即刻给予益母草注射液2ml/次肌肉注射,术后每天2次,建议连续使用1~3天。血止停药。观察患者术后阴道出血时间、合并用药、实验室检查、不良反应等情况。 可按照常规给予抗生素预防感染等其它措施的基础治疗。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Immediately after the abortion, placement or removal of the IUD, motherwort injection was given 2ml/ time intramuscular injection, twice a day after the operation, and continuous use for 1-3 days was recommended. Blood stop drug. Postoperative vaginal bleeding time, combined medication, laboratory tests and adverse reactions were observed. Basic treatment, such as antibiotics to prevent infection, can be routinely given. |
||||||||||||||||||||||
|
纳入标准: |
(1)人工流产术后 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) After induced abortion |
||||||||||||||||||||||
|
排除标准: |
1)对本品或含有益母草制剂及成分中所列辅料过敏或有严重不良反应病史者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Allergy to this product or excipients listed in motherwort preparation and ingredients or history of serious adverse reactions |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-10-09 00:00:00至 To 2021-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-10-10 00:00:00 至 To 2021-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
真实世界研究,不设随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Real world research, no random |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
项目结束后6个月,在本平台公开数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
6 months after the end of the project, publish data on this platform |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例报告表采取数据; 由第三方管理数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use case report form to collect data; Manage data by a third party |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |